The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.
Keywords: Bevacizumab; Coats’ disease; choroidal neovascularization; familial exudative vitreoretinopathy; retinopathy of prematurity; sickle cell retinopathy.